We currently manufacture and market a comprehensive portfolio of 56 modernized traditional Chinese medicines and pharmaceuticals designed to address large market opportunities. 23 of our current products are listed in the National Medicine Catalog of the National Medical Insurance Program, a government-administered medical insurance and reimbursement program.

Our products address significant medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology, pediatrics, among others. Approximately half of our products are prescription medicines while the remaining are intended for the over-the-counter sales.